Ashfaq Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ashfaq Ahmed has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Shaki Mostaid
Department of Pharmaceutical Sciences North South University Dhaka Bangladesh
2 shared publications - A.A.M. Sharfuddin
School of Pharmacy, Brac University, 66 Mohakhali, Dhaka, Bangladesh
1 shared publication A.E. Maisha Rawshan
Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh
1 shared publication- Abu S. M. Mohsin
BRAC University
1 shared publication Afrida Malik
Department of Electrical and Electronics Engineering, Brac University, 66 Mohakhali, Dhaka, Bangladesh
1 shared publication- Afrin Hossain Puspita
Department of Electrical and Electronics Engineering, Brac University, 66 Mohakhali, Dhaka, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Health, Utan Kayu Publishing in Journal of Current Health Sciences
- Vol. 6 (3) , 147-162
Oxidative Stress Induced Thrombosis and Hypercholesterolemic Condition in COVID-19 Infection
The COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a global health crisis, with severe disease and mortality disproportionately affecting individuals with comorbidities such as cardiovascular disease, diabetes, obesity, and immunosuppression. These conditions are associated with elevated basal reactive oxygen species (ROS) levels, predisposing patients to oxidative stress, systemic inflammation, endothelial dysfunction, and thrombotic complications. SARS-CoV-2 infection further exacerbates ROS generation via dysregulation of the renin–angiotensin system, NADPH oxidase activation, and immune-mediated neutrophil and macrophage responses, contributing to vascular injury, cytokine storm, and acute respiratory distress syndrome (ARDS). Hypercholesterolemic patients are particularly vulnerable, as oxidized LDL (OxLDL) enhances ROS production, promotes neutrophil extracellular trap formation, and accelerates thrombosis, further compounding COVID-19 severity. COVID-19–associated coagulopathy is characterized by elevated D-dimer, von Willebrand factor, and platelet activation, reflecting systemic hypercoagulability and multiorgan involvement. Therapeutically, targeting oxidative stress represents a promising strategy. Statins exhibit cholesterol-lowering and immunomodulatory effects, potentially reducing thrombotic risk. Nrf2 activators, glutathione, and N-acetylcysteine enhance endogenous antioxidant defenses, mitigate inflammation, and preserve endothelial integrity. Micronutrients such as vitamins C, D, E, and selenium further support redox homeostasis and immune function. Collectively, in this narrative review we have shown that understanding the interplay between oxidative stress, thrombosis, hypercholesterolemia, and immune dysregulation may inform preventive and therapeutic strategies to improve outcomes in high-risk COVID-19 patients. Clinical trials are warranted to validate the efficacy of these interventions.
- 20 May 2026
- Published by Health, Utan Kayu Publishing in Journal of Current Health Sciences
- Vol. 6 (3) , 147-162
Open AccessOxidative Stress Induced Thrombosis and Hypercholesterolemic Condition in COVID-19 Infection
The COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a global health crisis, with severe disease and mortality disproportionately affecting individuals with comorbidities such as cardiovascular disease, diabetes, obesity, and immunosuppression. These conditions are associated with elevated basal reactive oxygen species (ROS) levels, predisposing patients to oxidative stress, systemic inflammation, endothelial dysfunction, and thrombotic complications. SARS-CoV-2 infection further exacerbates ROS generation via dysregulation of the renin–angiotensin system, NADPH oxidase activation, and immune-mediated neutrophil and macrophage responses, contributing to vascular injury, cytokine storm, and acute respiratory distress syndrome (ARDS). Hypercholesterolemic patients are particularly vulnerable, as oxidized LDL (OxLDL) enhances ROS production, promotes neutrophil extracellular trap formation, and accelerates thrombosis, further compounding COVID-19 severity. COVID-19–associated coagulopathy is characterized by elevated D-dimer, von Willebrand factor, and platelet activation, reflecting systemic hypercoagulability and multiorgan involvement. Therapeutically, targeting oxidative stress represents a promising strategy. Statins exhibit cholesterol-lowering and immunomodulatory effects, potentially reducing thrombotic risk. Nrf2 activators, glutathione, and N-acetylcysteine enhance endogenous antioxidant defenses, mitigate inflammation, and preserve endothelial integrity. Micronutrients such as vitamins C, D, E, and selenium further support redox homeostasis and immune function. Collectively, in this narrative review we have shown that understanding the interplay between oxidative stress, thrombosis, hypercholesterolemia, and immune dysregulation may inform preventive and therapeutic strategies to improve outcomes in high-risk COVID-19 patients. Clinical trials are warranted to validate the efficacy of these interventions.
- Open Access
Design optimization and validation of UV-C illumination chamber for filtering facepiece respirators
- 23 December 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 82, 105411
Association of CD58 rs12044852 and rs2300747 polymorphisms with the risk of multiple sclerosis: A systematic review and meta-analysis
- 23 December 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 82, 105411
Association of CD58 rs12044852 and rs2300747 polymorphisms with the risk of multiple sclerosis: A systematic review and meta-analysis